Total Funding
75
47
Total FundingSeries A raised
Growth Score
-14 pts
Heat Score
-28 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
24866
Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of life threatening diseases.
- Jennifer Schneider: Chief Executive Officer & DirectorPast Role: Tiber Creek Partners, Principal
Jessica Boyle: VP of OperationsPast Role: Centauri Therapeutics, Head - Project Management & Business Operations
About the Company
Centauri is developing novel immunotherapeutics with a dual mechanism of action comprising (1) a moiety directly targeting cell surface antigens and (2) a glycan effector domain which triggers a potent pre-existing polyclonal immune response. This immune response triggers cell death through engagement with the target, enhanced complement fixation,
antibody dependent cellular cytotoxicity, and phagocytosis by myeloid cells due to polyclonal antibody decoration of the target cell. Centauri has generated excellent pre-clinical in vitro data demonstrating the potent enhancement of complement fixation and opsonophagocytosis of anti-bacterial and oncology therapeutics as well as in vivo PoC data in multiple models of infection.
